Daniel O'Day, Gilead CEO (Photo by Paras Griffin/Getty Images for ESSENCE)
August 4, 2023 05:15 AM EDT
Pharma

Gilead touts speed­i­er-than-ex­pect­ed pipeline ad­vances amid sol­id Q2 drug sales, ex­cept Covid-19 treat­ment Vek­lury

Beth Snyder Bulik

Senior Editor

The key qual­i­fy­ing phrase to Gilead Sci­ences’ sol­id sec­ond quar­ter earn­ings was “ex­clud­ing Vek­lury.” That’s be­cause the Covid-19 treat­ment was the spoil­er dropoff in a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times